Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983091 | 1.00 | CNR1 (0.39) | CNR1KMT2AALDH1A1POLBGAA | |
| SCHEMBL3980986 | 0.94 | CNR1 (0.37) | CNR1KMT2AALDH1A1GAANPSR1 | |
| SCHEMBL3980984 | 0.94 | CNR1 (0.37) | CNR1KMT2AALDH1A1GAANPSR1 | |
| SCHEMBL3987361 | 0.94 | CNR1 (0.39) | CNR1KMT2AALDH1A1RORC | |
| SCHEMBL3987362 | 0.94 | CNR1 (0.39) | CNR1KMT2AALDH1A1RORC | |
| SCHEMBL3983655 | 0.92 | CNR1 (0.36) | CNR1KMT2AALDH1A1 | |
| SCHEMBL3983680 | 0.92 | CNR1 (0.36) | CNR1KMT2AALDH1A1 | |
| SCHEMBL6662514 | 0.90 | KMT2A (0.39) | CNR1KMT2AOPRD1OPRK1 | |
| SCHEMBL3979429 | 0.90 | RHOC (0.39) | — | |
| SCHEMBL3979427 | 0.90 | RHOC (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560549-B2 | Sulfonyloxy derivatives | SANKYO COMPANY, LIMITED (JP) | 2009-07-14 | — | — | US | claimed |
| US-20070135434-A1 | Sulfonyloxy derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | claimed |
| EP-1754701-A1 | SULFONYLOXY DERIVATIVES | Sankyo Company, Limited (JP) | 2007-02-21 | — | — | EP | claimed |
| US-7560549-B2 | Sulfonyloxy derivatives | SANKYO COMPANY, LIMITED (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20070135434-A1 | Sulfonyloxy derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1754701-A1 | SULFONYLOXY DERIVATIVES | Sankyo Company, Limited (JP) | 2007-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135434-A1 | Sulfonyloxy derivatives | TACR1, NPSR1, TACR2 | CNR1 20/4885KMT2A 804/4885ALDH1A1 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.